Michael H. Baumann received his Ph.D. in Physiology and Neurobiology from Rutgers University in 1991. His dissertation research examined the involvement of endogenous opioid peptides in regulating pituitary hormone secretion. Dr. Baumann joined the National Institute on Drug Abuse (NIDA) Intramural Research Program (IRP) in 1991 as a Staff Fellow in the laboratory of Dr. Richard B. Rothman. From 1991-2011, Dr. Baumann and his colleagues elucidated the important role of brain dopamine and serotonin in the mechanism of action for various therapeutic and abused stimulant drugs. Over the years, Dr. Baumann was promoted to Senior Staff Fellow, Research Biologist, and finally to his current position as Staff Scientist. He joined the laboratory of Dr. Amy H. Newman in 2012 and established the Designer Drug Research Unit (DDRU). The main goal of the DDRU is to collect, analyze and disseminate current information about the pharmacology and toxicology of newly-emerging synthetic drugs of abuse (i.e., designer drugs). Working with partner organizations such as the Drug Enforcement Administration (DEA) and the National Drug Early Warning System (NDEWS), Dr. Baumann is kept informed about recent trends in designer drug use, and his laboratory has determined the molecular mechanism of action for many of the “bath salts” cathinones. The DDRU has enabled NIDA to remain at the forefront of research endeavors aimed at addressing the global epidemic of designer drug abuse.